Mario Sánchez-Borges1,2, Arnaldo Capriles-Hulett3, Jose Antonio Ortega-Martell4, Ignacio Ansotegui Zubeldia5. 1. Allergy and Clinical Immunology Department, Centro Médico Docente La Trinidad, Caracas, Venezuela. sanchezbmario@gmail.com. 2. Clínica El Avila, 6a transversal Urb. Altamira, piso 8, consultorio 803, Caracas, 1060, Venezuela. sanchezbmario@gmail.com. 3. Allergy and Clinical Immunology Department, Centro Médico Docente La Trinidad, Caracas, Venezuela. 4. School of Medicine, Autonomous University of Hidalgo State, Pachuca, Hidalgo, Mexico. 5. Department of Allergy and Immunology, Hospital Quironsalud, Bilbao, Bizkaia, Spain.
Abstract
PURPOSE OF REVIEW: An update on new therapies currently approved or potentially useful in the future for the management of patients suffering moderate-to-severe atopic dermatitis. RECENT FINDINGS: New pathogenic mechanisms involved in atopic dermatitis have permitted to propose novel therapeutic approaches devised to control the inflammatory process observed in involved cutaneous tissues by neutralizing mediators, cytokines, and their receptors. Recent research findings have disclosed important and previously unrecognized pathogenic mechanisms that have resulted in innovative targeted therapies, such as dupilumab, and potentially other biologicals and small molecules. Further studies should permit the sub-classification of patients according to the relevance of different mediators and inflammatory cells. It can be concluded that the treatment of atopic dermatitis has entered into the era of personalized/precision medicine.
PURPOSE OF REVIEW: An update on new therapies currently approved or potentially useful in the future for the management of patients suffering moderate-to-severe atopic dermatitis. RECENT FINDINGS: New pathogenic mechanisms involved in atopic dermatitis have permitted to propose novel therapeutic approaches devised to control the inflammatory process observed in involved cutaneous tissues by neutralizing mediators, cytokines, and their receptors. Recent research findings have disclosed important and previously unrecognized pathogenic mechanisms that have resulted in innovative targeted therapies, such as dupilumab, and potentially other biologicals and small molecules. Further studies should permit the sub-classification of patients according to the relevance of different mediators and inflammatory cells. It can be concluded that the treatment of atopic dermatitis has entered into the era of personalized/precision medicine.
Entities:
Keywords:
Atopic dermatitis; Biologicals; Dupilumab; Eczema; Small molecules; Treatment
Authors: Thomas Ruzicka; Jon M Hanifin; Masutaka Furue; Grazyna Pulka; Izabela Mlynarczyk; Andreas Wollenberg; Ryszard Galus; Takafumi Etoh; Ryosuke Mihara; Hiroki Yoshida; Jonathan Stewart; Kenji Kabashima Journal: N Engl J Med Date: 2017-03-02 Impact factor: 91.245
Authors: U Nygaard; M Hvid; C Johansen; M Buchner; R Fölster-Holst; M Deleuran; C Vestergaard Journal: J Eur Acad Dermatol Venereol Date: 2016-05-06 Impact factor: 6.166
Authors: Y Sano; K Masuda; R Tamagawa-Mineoka; H Matsunaka; Y Murakami; R Yamashita; E Morita; N Katoh Journal: Clin Exp Immunol Date: 2013-03 Impact factor: 4.330